🇪🇺 GADOFOSVESET TRISODIUM in European Union

EMA authorised GADOFOSVESET TRISODIUM on 3 October 2005

Marketing authorisation

EMA — authorised 3 October 2005

  • Application: EMEA/H/C/000601
  • Marketing authorisation holder: TMC Pharma Services Ltd.
  • Local brand name: Ablavar (previously Vasovist)
  • Indication: This medicinal product is for diagnostic use only. Ablavar is indicated for contrast-enhanced magnetic resonance angiography (CE-MRA) for visualisation of abdominal or limb vessels in adults only, with suspected or known vascular disease.
  • Status: withdrawn

Read official source →

GADOFOSVESET TRISODIUM in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is GADOFOSVESET TRISODIUM approved in European Union?

Yes. EMA authorised it on 3 October 2005.

Who is the marketing authorisation holder for GADOFOSVESET TRISODIUM in European Union?

TMC Pharma Services Ltd. holds the EU marketing authorisation.